Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;53(1):179-184.
doi: 10.1007/s42770-021-00648-3. Epub 2021 Nov 5.

Antimicrobial effect of Casiopeinas® copper- and ruthenium-based compounds on Aggregatibacter actinomycetemcomitans and in vitro cell viability onto osteoblasts cells

Larios-Cervantes Alexis Alberto  1 , Chávez-Cortéz Elda Georgina  1 , Martínez-Hernández Miryam  2 , Talavera-Contreras Luis Gabriel  3 , Espinoza-Guillen Adrian  3 , Carrillo-Ávila Bertha Arelly  1 , Ruiz-Azuara Lena  3 , Álvarez-Pérez Marco Antonio  4 , Martínez-Aguilar Victor Manuel  5
Affiliations

Antimicrobial effect of Casiopeinas® copper- and ruthenium-based compounds on Aggregatibacter actinomycetemcomitans and in vitro cell viability onto osteoblasts cells

Larios-Cervantes Alexis Alberto et al. Braz J Microbiol. 2022 Mar.

Abstract

Objectives: The present study aims to evaluate the antimicrobial property of Casiopeinas® copper- and ruthenium-based compounds against Aggregatibacter actinomycetemcomitans serotype b (ATCC® 43,718™), as well as the cytotoxicity on an osteoblasts cell line of both compounds.

Material and methods: The antibacterial effect of the copper-based compounds (CasII-gly, CasIII-ia) and the ruthenium-based compound (RuN-6) at four different concentrations was evaluated as the inhibition ratio of the bacterial growth after 48 h under anaerobic conditions, and the cell viability was measured through resazurin assay.

Results: The copper- and ruthenium-based compounds used for this assay were (CasII-gly, CasIII-ia, and RuN-6), showing inhibitory activity between 39 and 62% compared to the antibiotic employed as control 66%. Cell viability was established between 61 and 96%.

Conclusions: Casiopeinas® and ruthenium showed dose and time dependent, inhibitory activity on A. actinomycetemcomitans, and low toxicity on cells (osteoblast) underexposure. The compound CasII-gly showed the best antimicrobial effect, and it could be considered a possible antimicrobial agent in periodontal therapy.

Keywords: Aggregatibacter actinomycetemcomitans; Antimicrobial effect; Casiopeinas®; Copper; Ruthenium.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Statistical comparisons of mean absorbances obtained from the inhibition assay against Aggregatibacter actinomycetemcomitans with Cas II-gly, CassIII-ia, and RuN-6 treatments. A: antibiotic; C: culture medium; CasII-gly: Casiopeíne II-gly; CasII-ia: Casiopeíne III-ia: RuN-6: rutenio;Concentration: A (1) = 10 mg/mL, A (2) = 30 mg/mL, A (3) = 50 mg/mL, A (4) = 70 mg/mL; CasII-gly/CassIII-ia (1) = 4.31 μM, CasII-gly/CassIII-ia (2) = 12.94 μM, CasII-gly/CassIII-ia (3) = 21.57 μM, CasII-gly/CassIII-ia (4) = 30.20 μM; RuM-6 (1) = 2.09 μM, RuM-6 (2) = 6.28 μM, RuM-6 (3) = 10.48 μM, RuM-6 (4) = 14.67 μM. Different letters show statistical differences at p < 0.05
Fig. 2
Fig. 2
Statistical comparisons of mean absorbances obtained from osteoblastic culture with Cas II-gly, CassIII-ia, and RuN-6 compounds in the resazurin microtitration assay. A: antibiotic; C: culture medium; CasII-gly: Casiopeíne II-gly; CasII-ia: Casiopeíne III-ia: RuN-6: rutenio;Concentration: A (1) = 10 mg/mL, A (2) = 30 mg/mL, A (3) = 50 mg/mL, A (4) = 70 mg/mL; CasII-gly/CassIII-ia (1) = 4.31 μM, CasII-gly/CassIII-ia (2) = 12.94 μM, CasII-gly/CassIII-ia (3) = 21.57 μM, CasII-gly/CassIII-ia (4) = 30.20 μM; RuM-6 (1) = 2.09 μM, RuM-6 (2) = 6.28 μM, RuM-6 (3) = 10.48 μM, RuM-6 (4) = 14.67 μM. Different letters show statistical differences at p < 0.05
See this image and copyright information in PMC

References

    1. Papapanou PN, Sanz M, Buduneli N, Dietrich T, et al. Periodontitis: Consensus report of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Clin Periodontol. 2018;45(20):162–170. doi: 10.1111/jcpe.12946. - DOI - PubMed
    1. Chapple ILC, Mealey BL, Van Dyke TE, Bartold PM, et al. Periodontal health and gingival diseases and conditions on an intact and a reduced periodontium: Consensus report of workgroup 1 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Clin Periodontol. 2018;45(20):68–77. doi: 10.1111/jcpe.12940. - DOI - PubMed
    1. Asikainen S. Chen C (1999) Oral ecology and person-to-person transmission of Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis. Periodontol. 2000;20:65–81. doi: 10.1111/j.1600-0757.1999.tb00158.x. - DOI - PubMed
    1. Herbert BA, Novince CM, Kirkwood KL. Aggregatibacter actinomycetemcomitans, a potent immunoregulator of the periodontal host defense system and alveolar bone homeostasis. Mol Oral Microbiol. 2016;31(3):207–227. doi: 10.1111/omi.12119. - DOI - PMC - PubMed
    1. Bechara Andere NMR, dos Santos NCC, Araujo CF, Mathias IF, et al. Evaluation of the local effect of non-surgical periodontal treatment with and without systemic antibiotic and photodynamic therapy in generalized aggressive periodontitis. A randomized clinical trial. Photodiagnosis Photodyn Ther. 2018;24:115–120. doi: 10.3390/pharmaceutics13060836. - DOI - PubMed

LinkOut - more resources